Alaric has been covering the biopharma industry and health care for more than 14 years. His areas of focus include clinical trials, drug development in hematology-oncology, cell and gene therapy and the industry's growing use of artificial intelligence and machine learning. He holds a bachelor's degree in journalism from Ball State University and previously lived in China for three years.

Latest from Alaric DeArment

Anticipation – And Trepidation – About Trump’s Election Rise

The recent US presidential election was foremost on many speakers’ minds at the Galien Forum, with many expressing uncertainty about what a new Trump administration will bring in areas ranging from the Inflation Reduction Act (IRA) to funding for the National Institutes of Health.

Gilead Gears Up For CAR-T Data At ASH As Competition Weighs On Yescarta

The drug maker said in its third quarter earnings report that competition from other therapeutic classes, particularly bispecifics, resulted in a slight decline of sales for the CAR-T.

Beam Is Laser-Focused On ASH As It Reports Promising Sickle Cell Data, And A Death

The otherwise encouraging data were marred by one patient death, but the company attributed it to the busulfan conditioning regimen and not BEAM-101.

BNT327 Takes Leading Role In BioNTech’s Oncology Strategy In Q3

The biotech company is pushing the anti-PD-L1xVEGF-A bispecific antibody into Phase III, where it has potential to beat Akeso/Summit’s ivonescimab to market.

Merck Winning With Winrevair, Guarded On Gardasil In Q3

Third quarter sales for PAH drug Winrevair came in better than expected, while issues in China continued weighing on Gardasil.

BioFuture Notebook: Struggling With Innovation, Financing And Reimbursement

Panels at the recent BioFuture conference focused on the next breakthroughs in areas such as oncology and neurodegenerative diseases, continuing challenges to GLP-1 agonists, financing and how use of AI is taking shape.